NEW YORK (GenomeWeb News) – Response Genetics today said that it has extended an agreement with Taiho Pharmaceutical to provide testing and analysis services.
The Los Angeles-based molecular diagnostic firm will provide its services for molecular markers used in research diagnostics and the therapeutic treatment of cancer, it said, adding it will receive at least $950,000 for services provided during the extended period of Jan. 1 to Dec. 31, 2013.
Response and Tokyo-based Taiho first collaborated in 2001.
"Response Genetics has and continues to provide Taiho with a comprehensive portfolio of gene expression assays … and we believe that the testing services resulting from this collaboration will yield actionable results important to patient care," Response Genetics Chairman and CEO Thomas Bologna said in a statement.